Skip to main content
. 2018 Jun 22;3:16. doi: 10.1038/s41392-018-0019-4

Fig. 5.

Fig. 5

Co-encapsulation of CsA and Gef results in improved therapeutic efficacy in an acquired EGFR-TKI-resistant PC-9-GR tumor-bearing mouse model. a The tumor volume (mm3) change is presented as a function of time after drug treatment. When the tumor volume reached approximately 120 mm3, NP solutions were IV injected three times (indicated by green arrows). Free CsA and/or free Gef were orally administered (shown in red arrows). Saline was intravenously injected as a control. b Body weight gain/loss profiles of mice upon treatment. c Image showing tumors excised from the mice. d The tumor tissue weight on day 18, the endpoint of the study